NYSE:ARA American Renal Associates (ARA) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free ARA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$11.33▼$11.5250-Day Range$11.46▼$11.5252-Week Range$5.57▼$11.98Volume9,831 shsAverage Volume106,940 shsMarket Capitalization$397.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get American Renal Associates alerts: Email Address Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About American Renal Associates Stock (NYSE:ARA)American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.Read More Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. ARA Stock News HeadlinesAugust 31, 2023 | benzinga.comBayer's Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of CardiologyFebruary 22, 2023 | finance.yahoo.comAnemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateApril 29, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)January 11, 2023 | finance.yahoo.comLiberation From Renal Replacement Therapy and Early Initiation to Be Supported by The Kidney Function Biomarker Proenkephalin A 119-159 (penKid)January 2, 2023 | finance.yahoo.comContinuous Renal Replacement Therapy Global Market Report 2022: Rising Prevalence of Acute Kidney Injuries Drives DemandOctober 7, 2022 | bbc.comDalian Atkinson: Footballer killed hours before renal treatmentJune 22, 2022 | finance.yahoo.comARA Appoints James Myers Vice President, Program Innovation and GrowthJune 20, 2022 | thestreet.comAmerican Renal Associates Holdings, Inc. NewsApril 29, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)December 6, 2021 | markets.businessinsider.comSEC Charges Dialysis Provider and Three Former Senior Executives with Revenue Manipulation SchemeDecember 6, 2021 | law360.comSEC Hits Dialysis Co., Execs With Accounting Fraud ClaimDecember 6, 2021 | nasdaq.comU.S. SEC charges dialysis provider, three former executives with revenue manipulationOctober 21, 2021 | sg.finance.yahoo.comStrive Health Unveils Strive Care Partners, Reaches 500 Nephrology PartnersOctober 19, 2021 | investing.comAmerican Renal Associates Holdings Inc (ARA)See More Headlines Receive ARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2020Today4/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolNYSE:ARA CUSIPN/A CIK1498068 Webwww.americanrenal.com Phone978-922-3080FaxN/AEmployees4,977Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.26 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,790,000.00 Net Margins-2.04% Pretax MarginN/A Return on Equity-3.56% Return on Assets-0.24% Debt Debt-to-Equity Ratio7.54 Current Ratio1.05 Quick Ratio1.02 Sales & Book Value Annual Sales$822.52 million Price / Sales0.48 Cash Flow$1.69 per share Price / Cash Flow6.80 Book Value$2.59 per share Price / Book4.45Miscellaneous Outstanding Shares34,543,000Free FloatN/AMarket Cap$397.94 million OptionableOptionable Beta1.11 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Joseph A. Carlucci (Age 66)Co-Founder, CEO & Chairman Comp: $1.06MMr. Syed T. Kamal (Age 67)Co-Founder, Pres & Director Comp: $947.14kDr. Don E. Williamson (Age 58)Exec. VP & COO Comp: $1.22MMr. Mark C. Herbers (Age 65)Interim CFO & Interim Chief Accounting Officer Mr. Richard Pacheco CFEAVA, MBA, VP of Admin.Mr. Neal MinahanChief Compliance Officer & VPMs. Victoria A. Labriola Esq.M.B.A., VP, Gen. Counsel & Sec.Ms. Jennifer HoodVP of HRDr. Richard Cronin M.D.Chief Medical OfficerMs. Shari Cousins R.N.C.N.N., Sr. VP of Clinical & Regulatory ServicesMore ExecutivesKey CompetitorsBeauty HealthNASDAQ:SKINMaxCyteNASDAQ:MXCTCorbus PharmaceuticalsNASDAQ:CRBPAnnexonNASDAQ:ANNXLexeo TherapeuticsNASDAQ:LXEOView All Competitors ARA Stock Analysis - Frequently Asked Questions How were American Renal Associates' earnings last quarter? American Renal Associates Holdings, Inc. (NYSE:ARA) posted its quarterly earnings data on Wednesday, November, 11th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.06 by $0.09. The firm had revenue of $209.69 million for the quarter, compared to the consensus estimate of $211.50 million. American Renal Associates had a negative trailing twelve-month return on equity of 3.56% and a negative net margin of 2.04%. What is Joseph Carlucci's approval rating as American Renal Associates' CEO? 62 employees have rated American Renal Associates Chief Executive Officer Joseph Carlucci on Glassdoor.com. Joseph Carlucci has an approval rating of 57% among the company's employees. This puts Joseph Carlucci in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of American Renal Associates own? Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include Zevra Therapeutics (KMPH), Exelixis (EXEL), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Spectrum Pharmaceuticals (SPPI), Akorn (AKRX), Fate Therapeutics (FATE), Karyopharm Therapeutics (KPTI) and Kura Oncology (KURA). When did American Renal Associates IPO? American Renal Associates (ARA) raised $161 million in an IPO on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers. This page (NYSE:ARA) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding American Renal Associates Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.